Haematologica Reports 2006; 2(issue 3): 29-31[prev][index][next]
Towards therapeutic stimulations of gd T cells
Malkovsky M,1 Wallace M,1 McNeel DG,1 Liu G,1 Mejia G,1 Kaikobad M,1 Waterman P,1
Samaniego E,1 Bonneville M,2 Fournie JJ,3 Sicard H,4 Poccia F,5
1University of Wisconsin Medical School, Madison, WI, USA; 2INSERM U601, Institut de
Biologie, Nantes, France; 3INSERM U395, Toulouse,France; 4Innate Pharma, Marseille, France; 5Laboratory of Cellular Immunology, National Institute for Infectious Diseases
"L.Spallanzani", Rome, Italy
Most vaccine strategies are designed to elicit adaptive immune responses to a variety of microbial or tumor-associated antigens. These immune responses are predominantly mediated by αβ T cells, B cells and antibodies. Nevertheless, approximately 1-5% of human peripheral blood lymphocytes possess the surface gd T-cell receptor, predominantly expressing the Vγ9Vδ2 variable segments.
[>Read full article in PDF]
